[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group].
Guastalla
J P
JP
Centre Léon Bérard, Lyon, France.
Pujade-Lauraine
E
E
Colombo
N
N
Namer
N
N
Fumoleau
P
P
Monnier
A
A
Nooy
M A
MA
Falkson
G
G
Mignot
L
L
Bugat
R
R
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007371:Interferon-gamma / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D007371:Interferon-gamma
Efficacité de l'interféron gamma recombinant (RU 42369) administré par voie intra-péritonéale dans les carcinomes ovariens. European BRM Study Group.